Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH) is forecasted to achieve a net profit of 493 million to 541 million yuan in 2024, an increase of 0.01% to 9.86% year-on-year.

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH) announced that the company is expected to achieve a net profit attributable to the owners of the parent company of 493 million to 541 million yuan in 2024, compared to the same period last year, an increase of 680 thousand to 4856.8 million yuan, with a year-on-year increase of 0.01% to 9.86%. During the reporting period, the company's innovative products Castor branch aortic endovascular stent and delivery system, Minos abdominal aortic endovascular stent and delivery system, and Reewarm PTX drug balloon dilation catheter continued to perform well. The new products Talos straight tube thoracic aortic endovascular stent system and Fontus branch endovascular stent system showed rapid growth in hospital admissions and terminal implants. However, considering the market environment changes in the second half of the year, the company's sales growth and profit were affected to a certain extent by factors such as adjustments in product prices and promotion strategies.